Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Street Poller Media and The Boom of the Street Interview Ad Industry 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Shein Shares Slide 9% in Hong Kong IPO Debut 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Add as a preferred source on Google
MORRISVILLE, N.C., March 29, 2018 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Thursday, April 12, at 8:30 a.m. Eastern Time to provide an update on the Company’s activities and progress. A moderated question and answer session will be available after the update. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States and Canada) or +1 (703) 318-2240 (international). The conference ID for the live call is 9393869. A live webcast will be accessible from the Events page of the Company’s website at http://Events.Novan.com. The webcast will be archived on the Company’s website for 7 days following the live call.
About Novan
Novan, Inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. We believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.
CONTACT:
(Investors)
Novan, Inc.
[email protected]
(Media)
Cari Green
Director, Corporate Communications and Administration
[email protected]
